# Profound Medical

Type: Company (PROF)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/profound-medical
Canonical HTML page: https://gethealthbrief.com/entity/profound-medical

## Timeline

- **2026-03-05**: Earnings Release — Companies report Q4 and Full Year 2025 results, signaling a shift to 2026 commercial targets.
- **2025-12-31**: Fiscal Year End — Med-tech firms report record system utilization rates for the 2025 calendar year.
- **2025-06-20**: Clinical Enrollment — Atea Pharmaceuticals completes enrollment for the Phase 2 Hepatitis C (HCV) trial.
- **2025-03-15**: Reimbursement Milestone — Profound Medical receives expanded CPT code coverage for TULSA-PRO in the U.S.

## Recent coverage (2 stories)

### Kura and Profound Q4 Results: Pivotal 2026 for Precision Medicine
2026-03-06 05:15:19 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a critical transition period as they navigate commercial launches and reimbursement hurdles. While both firms faced revenue headwinds, Kura's $7 billion AML opportunity and Profound's significant EPS beat underscore a shifting landscape in oncology and incision-less surgery.
Full story: https://gethealthbrief.com/story/kura-oncology-profound-medical-q4-2025-earnings-analysis

### MedTech and Biotech Earnings: Profound Medical and Atea Signal 2026 Pivot
2026-03-05 22:41:33 · Sentiment: Neutral · Impact: 5/10 · Sources: 5

Atea Pharmaceuticals and Profound Medical headlined a series of Q4 2025 earnings reports, highlighting a shift toward commercial scaling in medical devices and late-stage clinical milestones in biotech. These results underscore a sector-wide focus on capital preservation and high-margin recurring revenue models.
Full story: https://gethealthbrief.com/story/medtech-biotech-earnings-q4-2025-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.